Related Experiment Videos
Thrombin and antithrombotic therapy in interventional cardiology
1Catheterization Laboratory, Thoraxcenter, Erasmus University, Rotterdam, The Netherlands.
Texas Heart Institute Journal
|January 1, 1994
Summary
Percutaneous transluminal coronary angioplasty has improved success rates, but restenosis remains a challenge. Research is focusing on thrombin inhibition to prevent reocclusion and improve long-term outcomes in angioplasty patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) offers high procedural success but is limited by early and late reocclusion.
- Despite technological advances, restenosis (late renarrowing) affects 15%-40% of patients, leading to angina recurrence.
Purpose of the Study:
- To review the challenges of restenosis after PTCA.
- To explore the role of thrombin in angioplasty-induced vascular injury.
- To discuss current pharmacologic strategies targeting thrombin to prevent reocclusion.
Main Methods:
- Review of multicenter randomized trials and animal experimental work.
- Focus on understanding the restenosis phenomenon and thrombin's role.
- Evaluation of antithrombotic medications targeting thrombin.
Main Results:
- PTCA procedural success rates are high (90%-95%), with low complication rates (4%-5%).
- Late reocclusion and angina recurrence remain significant issues in 15%-40% of patients.
- Thrombin is identified as a key factor in vascular injury post-angioplasty.
Conclusions:
- No major breakthroughs in preventing restenosis have been reported, but understanding has progressed.
- Pharmacologic research is concentrating on direct thrombin inhibition.
- Clinical trials are crucial to assess the safety, efficacy, and potential side effects of new antithrombotic therapies.